These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29714554)

  • 1. Optimal Anti-cancer Drug Profiles for Effective Penetration of the Anti-cancer Drug Market by Generic Drugs in Japan.
    Shibata S; Matsushita M; Saito Y; Suzuki T
    Ther Innov Regul Sci; 2018 Jul; 52(4):442-448. PubMed ID: 29714554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer Drug Prescription Patterns in Japan: Future Directions in Cancer Therapy.
    Shibata S; Matsushita M; Saito Y; Suzuki T
    Ther Innov Regul Sci; 2018 Nov; 52(6):718-723. PubMed ID: 29714569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generic Price Competition For Specialty Drugs: Too Little, Too Late?
    Cole AL; Dusetzina SB
    Health Aff (Millwood); 2018 May; 37(5):738-742. PubMed ID: 29733710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of being first: evidence from Canadian generic pharmaceuticals.
    Hollis A
    Health Econ; 2002 Dec; 11(8):723-34. PubMed ID: 12457372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential impact of policy regulation and generic competition on sales of cholesterol lowering medication, antidepressants and acid blocking agents in Belgium.
    Fraeyman J; Van Hal G; De Loof H; Remmen R; De Meyer GR; Beutels P
    Acta Clin Belg; 2012; 67(3):160-71. PubMed ID: 22897063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Analysis Between the Top-Selling Drugs in the Japanese Pharmaceutical Market and Those in the United States, the United Kingdom, France, and Germany.
    Shibata S; Uemura R; Suzuki T
    Ther Innov Regul Sci; 2016 Mar; 50(2):221-227. PubMed ID: 30227003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diffusion of generics after patent expiry in Germany.
    Fischer KE; Stargardt T
    Eur J Health Econ; 2016 Nov; 17(8):1027-1040. PubMed ID: 26573841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the Effectiveness of Repricing for Market Expansion in the Japanese Drug Pricing System.
    Shibata S; Uemura R; Suzuki T
    Ther Innov Regul Sci; 2016 Nov; 50(6):751-758. PubMed ID: 30231734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Economy of generic drugs in Latin America].
    Tobar F
    Rev Panam Salud Publica; 2008 Jan; 23(1):59-67. PubMed ID: 18291074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
    Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
    JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China.
    Guan X; Tian Y; Ross-Degnan D; Man C; Shi L
    BMJ Open; 2018 Jul; 8(7):e022328. PubMed ID: 30012792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated trends in US brand-name and generic drug competition.
    Grabowski H; Long G; Mortimer R; Boyo A
    J Med Econ; 2016 Sep; 19(9):836-44. PubMed ID: 27064194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of generic competition on prescription to over-the-counter switching.
    Hollenbeak CS
    Pharmacoeconomics; 1999 Dec; 16(6):661-8. PubMed ID: 10724793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of generic market entry on antibiotic prescriptions in the United States.
    Kållberg C; Hudson J; Salvesen Blix H; Årdal C; Klein E; Lindbæk M; Outterson K; Røttingen JA; Laxminarayan R
    Nat Commun; 2021 May; 12(1):2937. PubMed ID: 34006862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.
    Fraeyman J; Verbelen M; Hens N; Van Hal G; De Loof H; Beutels P
    Appl Health Econ Health Policy; 2013 Oct; 11(5):543-52. PubMed ID: 24062144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Competition between branded and generic drugs in Austria: evidence from the market for ACE inhibitors].
    Mahlich JC; Stadler I
    Gesundheitswesen; 2012 Jan; 74(1):23-8. PubMed ID: 21154203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of generic substitution on price competition in Finland.
    Aalto-Setälä V
    Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011.
    Cheng N; Banerjee T; Qian J; Hansen RA
    J Am Pharm Assoc (2003); 2017; 57(3):341-348. PubMed ID: 28400255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generic antibiotics in Japan.
    Fujimura S; Watanabe A
    J Infect Chemother; 2012 Aug; 18(4):421-7. PubMed ID: 22684334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.